Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance Wai-Jo Jocelin ChanJeffry AdiwidjajaJoanna E. Harnett Review Article Open access 27 January 2023 Pages: 103 - 119
Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions Zhuo LiQing ZhangLi-Bo Zhao Original Article 13 December 2022 Pages: 121 - 132
Value of whole-body dynamic 18F-FMISO PET/CT Patlak multi-parameter imaging for evaluating the early radiosensitizing effect of oleanolic acid on C6 rat gliomas Ke CaiQingqing ZhangHuiqin Xu Original Article 24 December 2022 Pages: 133 - 141
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration Fei GuoBingyan LiuHuan Zhou Original Article 27 December 2022 Pages: 143 - 156
The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer Cathrine F. HjorthPer DamkierDeirdre Cronin-Fenton Original Article Open access 04 January 2023 Pages: 157 - 165
A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions Hai-chuan SuJie MinHe-long Zhang Original Article 09 January 2023 Pages: 167 - 177
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma Benjamin Duy TranJing LiLorin Roskos Original Article Open access 10 January 2023 Pages: 179 - 189
The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo Müge SakBrian J. WilliamsNorman L. Lehman Original Article 25 January 2023 Pages: 191 - 201